Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.

Background And Aim: The optimal time to withdraw combined biological + immunosuppressive therapy in Crohn's disease is debated. Following remission of 6 months with the combined therapy, we assessed the efficacy of monotherapy in maintaining remission.

Methods: Crohn's disease patients (n = 75) were retrospectively selected from clinical records for having achieved remission within 6 months of receiving combined biological + immunosuppressive therapy.

Is safety infliximb during pregnancy in patients with inflammatory bowel disease?

Background: in most cases, inflammatory bowel disease (IBD) debuts at reproductive age. The data available in the literature show infliximab (IFX) to be a safe drug during pregnancy but there is very little evidence about the activity of the disease following drug withdrawal during pregnancy.

Aims: determine the drug's safety in pregnant women in our setting and assess its effect on the foetus, drawing on the experience of several hospitals.